**Appendix Table E95. Phenotypic test details in studies assessing the predictive ability of PFA-100 in patients with ischemic heart, cerebrovascular and peripheral vascular disease**

| **Author, year [ref]****UID****Country****Study Name** | **Test/Device name** **Device category Device name & manufacturer\*** | **Agonist used** | **Sample Collection and Procurement****Anticoagulant used****Interval between clopidogrel doses and blood sampling (in days)** **Interval between sampling and testing (in days):** | **Grouping of Phenotypes [Definition]**  | **Rational for the grouping of phenotypes reported (Yes/No)** **[short description]** | **Frequency of phenotypes**  |
| --- | --- | --- | --- | --- | --- | --- |
| Reny, 2012{Reny, 2012 18240 /id}22615340France and SwitzerlandADRIE | PFA-100platelet function analyzerThe PFA-100 (Dade Behring, Marburg, Germany) | Collagen and ADP | Blood samples collected after antiplatelet therapy intake0.105 mol/L sodium citrate (1vol/9 vol)3 hrsNR | CT<190s: CT>190s | based on literature | <190s: 310≥190: 339 |